- Conditions
- Brain and Central Nervous System Tumors
- Interventions
- ATN-161, carboplatin
- Drug
- Lead sponsor
- National Institutes of Health Clinical Center (CC)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 82 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 121–144
of 2,333
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Cerebellar Tumors, Brain Tumor
- Interventions
- Impact of Cerebellar Functional Topography on Cognition and Motor Ataxia
- Other
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 66 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Glioblastoma
- Interventions
- Optune
- Device
- Lead sponsor
- Baylor Research Institute
- Other
- Eligibility
- 22 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- Temple, Texas
- Conditions
- Glioblastoma
- Interventions
- DSP-7888 Dosing Emulsion, Bevacizumab
- Drug
- Lead sponsor
- Sumitomo Pharma America, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 221 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 37
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Fayetteville, Arkansas + 30 more
- Conditions
- Glioma, Glioblastoma, Astrocytoma, Oligodendroglioma, Brain Neoplasm
- Interventions
- Motexafin Gadolinium Injection
- Drug
- Lead sponsor
- Pharmacyclics LLC.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 1
- States / cities
- Phoenix, Arizona
- Conditions
- Adult Anaplastic Astrocytoma, Adult Anaplastic Oligodendroglioma, Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Recurrent Adult Brain Neoplasm
- Interventions
- Bendamustine Hydrochloride, Quality-of-Life Assessment
- Drug · Other
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2017
- U.S. locations
- 3
- States / cities
- Chicago, Illinois • Salt Lake City, Utah • Seattle, Washington
- Conditions
- Glioblastoma Multiforme
- Interventions
- TLN-4601
- Drug
- Lead sponsor
- Thallion Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 2
- States / cities
- New York, New York • Durham, North Carolina
- Conditions
- Diffuse Intrinsic Pontine Glioma, Brain Tumor, Recurrent, Solid Tumor, Recurrent, Neuroblastoma, Recurrent, Refractory, Ewing Sarcoma, Recurrent, Refractory, Rhabdomyosarcoma, Recurrent, Refractory, Osteosarcoma, Recurrent, Refractory, Rhabdoid Tumor, Recurrent, Refractory
- Interventions
- Abemaciclib
- Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- 2 Years to 25 Years
- Enrollment
- 53 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2023
- U.S. locations
- 4
- States / cities
- Phoenix, Arizona • Aurora, Colorado • Atlanta, Georgia
- Conditions
- Brain Tumors
- Interventions
- Poly ICLC
- Drug
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- Up to 21 Years
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2019
- U.S. locations
- 2
- States / cities
- San Diego, California • Atlanta, Georgia
- Conditions
- Leukemia, Brain Tumor, Solid Tumor, Lymphoma
- Interventions
- ALRN-6924, Cytarabine
- Drug
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 1 Year to 21 Years
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 4
- States / cities
- San Francisco, California • Boston, Massachusetts • Philadelphia, Pennsylvania + 1 more
- Conditions
- Craniotomy for Epilepsy and Malignant Tumor Removal
- Interventions
- Brain shift monitoring
- Device
- Lead sponsor
- Advanced Scanners Inc.
- Industry
- Eligibility
- 6 Years and older
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020
- U.S. locations
- 1
- States / cities
- Austin, Texas
- Conditions
- Brain and Central Nervous System Tumors, Lymphoma, Metastatic Cancer
- Interventions
- Melphalan
- Drug
- Lead sponsor
- OHSU Knight Cancer Institute
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1998 – 2016
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Atypical Teratoid/Rhabdoid Tumor, Embryonal Tumor With Multilayered Rosettes, Ewing Sarcoma, Diffuse Intrinsic Pontine Glioma, Osteosarcoma, Neuroblastoma, DIPG Brain Tumor
- Interventions
- Eflornithine (DFMO), AMXT 1501 Dicaprate
- Drug
- Lead sponsor
- Milton S. Hershey Medical Center
- Other
- Eligibility
- Up to 26 Years
- Enrollment
- 265 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2035
- U.S. locations
- 14
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • Hartford, Connecticut + 11 more
- Conditions
- Breast Cancer, Brain Metastases
- Interventions
- Whole Brain Radiotherapy (WBRT), Sorafenib
- Radiation · Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2022
- U.S. locations
- 6
- States / cities
- Basking Ridge, New Jersey • Middletown, New Jersey • Commack, New York + 3 more
- Conditions
- Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Lymphoproliferative Disorder, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- 3'-deoxy-3'-[18F]fluorothymidine
- Device
- Lead sponsor
- Barbara Ann Karmanos Cancer Institute
- Other
- Eligibility
- 18 Years to 120 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2027
- U.S. locations
- 1
- States / cities
- Detroit, Michigan
- Conditions
- Medulloblastoma, Ependymoma, Pineal Region Tumors, Choroid Plexus Tumors, Atypical/Malignant Meningioma
- Interventions
- Nivolumab, EKG, MRI Brain and/or spine, Body CT Scan, MDASI-BT, MDASI-SP
- Drug · Diagnostic Test · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 136 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2025
- U.S. locations
- 3
- States / cities
- Chicago, Illinois • Bethesda, Maryland • Houston, Texas
- Conditions
- Diffuse Intrinsic Pontine Glioma
- Interventions
- Bevacizumab, Erlotinib, Temozolomide, Radiation
- Drug · Radiation
- Lead sponsor
- Karen D. Wright MD
- Other
- Eligibility
- 3 Years to 18 Years
- Enrollment
- 53 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2016
- U.S. locations
- 23
- States / cities
- Phoenix, Arizona • Los Angeles, California • Palo Alto, California + 20 more
- Conditions
- Glioma, Meningioma
- Interventions
- Blood test
- Procedure
- Lead sponsor
- Marquette General Health System
- Other
- Eligibility
- Not listed
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2012
- U.S. locations
- 1
- States / cities
- Marquette, Michigan
- Conditions
- Brain and Central Nervous System Tumors
- Interventions
- chemotherapy, cladribine, radiation therapy
- Drug · Radiation
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1995
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Glioblastoma, Gliosarcoma
- Interventions
- Temodar, O6-BG, and Irinotecan
- Drug
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 96 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2008
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Cancer, Metastasis, Metastatic Cancer, Brain Metastases, Brain Metastases, Adult
- Interventions
- Azeliragon, Stereotactic radiosurgery, Corticosteroid
- Drug · Radiation
- Lead sponsor
- Baptist Health South Florida
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Brain Tumor
- Interventions
- Phenylbutyrate
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- Not listed
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2002
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Brain and Central Nervous System Tumors, Unspecified Childhood Solid Tumor, Protocol Specific
- Interventions
- valproic acid
- Drug
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- 2 Years to 21 Years
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2012
- U.S. locations
- 15
- States / cities
- Orange, California • Stanford, California • Washington D.C., District of Columbia + 12 more
- Conditions
- Small Cell Lung Cancer
- Interventions
- LY3295668 Erbumine
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 16
- States / cities
- Fayetteville, Arkansas • Denver, Colorado • Tampa, Florida + 12 more